Streetbeat News

Regulatory

ALZN

Alzamend Neuro has announced the initiation date for a Phase II clinical trial of AL001, a next-generation lithium treatment for Major Depressive Disorder, to be conducted at Massachusetts General Hospital.

Portfolio Pulse from

March 18, 2025 | 12:15 pm

AAPL

Apple has lost an appeal against Germany's special abuse control regime, meaning it will continue to face specific competition controls in Germany, alongside other European regulations like the EU's DMA.

Portfolio Pulse from

March 18, 2025 | 12:15 pm

INDP

Indaptus Therapeutics has initiated a new expansion arm of its Phase 1b/2 clinical trial to evaluate the combination of its drug Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab. The study will focus on safety, dose optimization, and early signs of anti-tumor activity.

Portfolio Pulse from

March 18, 2025 | 12:15 pm

OCGN

Ocugen, Inc. announced that the Data and Safety Monitoring Board has approved the continuation of the OCU200 clinical trial into the second cohort after reviewing safety data from the first cohort. OCU200 is a novel treatment for diabetic macular edema.

Portfolio Pulse from

March 18, 2025 | 12:15 pm

JNJ

Johnson & Johnson's investigational treatment, nipocalimab, has received Fast Track designation from the FDA for treating moderate-to-severe Sjögren's disease. This follows its earlier Breakthrough Therapy designation, highlighting its potential as a significant treatment option.

Portfolio Pulse from

March 18, 2025 | 12:15 pm

SCNX

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) has received FDA approval for its new product, ArbliTM, a losartan potassium oral suspension. This is the first FDA-approved ready-to-use oral liquid losartan in the U.S., targeting hypertension, stroke risk reduction, and diabetic nephropathy.

Portfolio Pulse from

March 18, 2025 | 12:15 pm

GPTRF

Grande Portage Resources Ltd. has initiated environmental and cultural baseline studies for its New Amalga Gold Project near Juneau. This step is crucial for the project's development and regulatory compliance.

Portfolio Pulse from

March 18, 2025 | 12:15 pm

SPGI

A new initiative, co-chaired by GCMU, Sylvera, RMI, and S&P Global Commodity Insights, aims to standardize carbon data to enhance transparency and scale carbon markets. The Carbon Data Open Protocol (CDOP) will harmonize definitions and rules for carbon crediting projects, improving market integrity.

Portfolio Pulse from

March 18, 2025 | 12:15 pm

SPGI

A new initiative, co-chaired by GCMU, Sylvera, RMI, and S&P Global Commodity Insights, aims to standardize carbon data to enhance transparency and scale carbon markets. The Carbon Data Open Protocol (CDOP) seeks to harmonize definitions and rules for carbon crediting projects, improving market integrity.

Portfolio Pulse from

March 18, 2025 | 12:15 pm

INDP

Indaptus Therapeutics has initiated a new expansion arm of its Phase 1b/2 clinical trial to evaluate the combination of its drug Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab. The study will focus on safety, dose optimization, and early signs of anti-tumor activity.

Portfolio Pulse from

March 18, 2025 | 12:15 pm